PFA
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Amerise Biosciences (formerly Amradeep Industries) reported audited FY25 results with revenue from operations of Rs. 18.80 lakhs, a sharp jump from Rs. 3.59 lakhs in FY24, though on a very small base. The company swung to a net profit of Rs. 0.57 lakh versus a loss of Rs. 14.61 lakh last year, with Q4 alone delivering Rs. 10.59 lakh in profit. Total assets grew to Rs. 846.33 lakhs (from Rs. 538.96 lakhs), driven mainly by higher loans and investments, while cash and equivalents stood at just Rs. 2.22 lakhs. Other equity remained negative at Rs. (122.71) lakhs, reflecting accumulated losses, and current liabilities surged to Rs. 308.35 lakhs (from Rs. 1.55 lakhs). Operating cash flow turned positive at Rs. 307.08 lakhs versus an outflow of Rs. 16.94 lakhs in FY24.
The company has returned to profitability and posted strong revenue growth, but the absolute numbers remain very small and the balance sheet still carries negative reserves, suggesting limited scale and ongoing business risk for shareholders. The clean (unmodified) auditor opinion is a positive, though the sharp rise in current liabilities warrants a closer look.